PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.
